Granules India Ltd has signed its first Master Services Agreement with GlaxoSmithKline Consumer Healthcare R&D for product development recently.
The agreement is part of the company's venture into contracts for product development with various partner companies, according to Mr Krishna Prasad, Managing Director.
The Hyderabad-based pharmaceutical formulation intermediates (PFIs) company has reported a 37.43 per cent jump in net profit at Rs 3.05 crore for the quarter ended December 31, 2006 against Rs 2.22 crore in the corresponding quarter last year.
Net sales during the quarter grew by 12.98 per cent to Rs 50.21 crore, compared with Rs 44.44 crore in the corresponding quarter of last fiscal.
Explaining the company's performance, Mr Krishna Prasad said Metformin API (active pharmaceutical intermediates) and PFIs have largely contributed to the growth. During the review period, Granules India also signed a memorandum of understanding with Hubei Biocause Hellen Pharmaceutical Company (Biocause) of China. It acquired a 50 per cent stake in the company to manufacture APIs, starting with Ibuprofen, of which Biocause is one of the biggest manufacturers and exporters globally.
The company also signed an MoU with PharmaMatch to develop, manufacture and market formulations in the European market jointly.
Taken from Business Line
Granules India stock price
On August 31, 2015, Granules India closed at Rs 124.25, up Rs 2.30, or 1.89 percent. The 52-week high of the share was Rs 134.00 and the 52-week low was Rs 52.51.
The company's trailing 12-month (TTM) EPS was at Rs 5.33 per share as per the quarter ended June 2015. The stock's price-to-earnings (P/E) ratio was 23.31. The latest book value of the company is Rs 20.76 per share. At current value, the price-to-book value of the company is 5.99.
READ MORE ON Granules India Ltd , GlaxoSmithKline Consumer , agreement, Krishna Prasad, Hyderabad, Ibuprofen, PharmaMatch
Set email alert for
ADS BY GOOGLE
video of the day
Sensex can slip to 22K, FY16 GDP sliced to 6.8%: Ambit Cap